Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price trimmed by Sanford C. Bernstein from $27.00 to $24 ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

Alight, Inc. , a leading cloud-based human capital and technology-enabled services provider, today announced that its Chief Financial Officer, Jeremy Heaton, will present at the UBS Global Technology ...

ProLynx Inc., a biotechnology company developing proprietary systems to extend the half-life, improve efficacy, and reduce toxicities of important therapies, today announced that research of the ...

11月26日宣布的Sarepta与Arrowhead Pharmaceuticals (NASDAQ:ARWR)的最新合作关系重新引发了投资者的浓厚兴趣。消息公布后，Sarepta股价在收盘时上涨了14%。这笔交易被视为一个积极举措，解决了人们对近期催化剂和长期可持续增长的担忧。

“华兴资本医疗与生命科技行业周报”定期发布，专注从资本角度解读一周数据，并提供最新行业观察。医疗与生命科技是华兴资本多年来关注并深耕的领域，目前已为近200个融资及并购项目担任财务顾问。医疗与生命科技行业创新不断涌现，已经发展成为最活跃的行业之一；华 ...

上周，重磅消息很多。 首当其冲的当然是国内医保谈判出结果，作为《全链条支持创新药发展实施方案》后的首次国家医保谈判，备受外界关注。

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Real Matters Inc. (TSE:REAL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six ratings ...